Main characteristics of individuals from whom BM aspirates were analyzed
| Entire patient cohort (N = 732) (n %) | |
| Age (median), y | 62 (15-91) |
| <40 y, N | 82 (11.2) |
| ≥40 to < 60 y, N | 237 (32.4) |
| ≥60 y, N | 413 (56.4) |
| Gender | |
| Female, N | 295 (40.6) |
| Male, N | 437 (59.7) |
| Diagnosis | |
| AML, N | 206 (28.1) |
| ALL, N | 35 (4.8) |
| CML, N | 13 (1.8) |
| CLL, N | 31 (4.2) |
| Other MPN, N | 11 (1.4) |
| MDS, N | 63 (8.6) |
| Hodgkin lymphoma, N | 12 (1.6) |
| Non-Hodgkin lymphoma, N | 141 (19.3) |
| Multiple myeloma, N | 97 (13.3) |
| Solid tumor, N | 90 (12.3) |
| Other hematological disease, N | 50 (6.8) |
| Healthy individual, N | 11 (1.5) |
| Therapy | |
| Allogeneic SCT, N | 196 (26.8) |
| Autologous SCT, N | 58 (7.9) |
| Prior chemotherapy, N | 435 (59.4) |
| Prior radiation, N | 186 (25.4) |
| Unknown, N | 45 (6.1) |
| alloSCT patient cohort (N = 196) | |
| Disease status at the time of alloSCT | |
| CR | 81 (41.3) |
| PR | 33 (16.8) |
| SD, refractory or progressive disease | 71 (36.2) |
| Unknown | 11 (5.7) |
| Conditioning regimen | |
| MAC | 34 (17.3) |
| RIC | 142 (72.4) |
| NMA | 14 (7.1) |
| Unknown | 6 (3.1) |
| GvHD prophylaxis | |
| CsA + MMF | 130 (66.3) |
| CsA + MTx | 43 (21.9) |
| CNI + MMF + PTCy | 9 (4.6) |
| Other/unknown | 14 (7.2) |
| Use of ATG | 153 (78.1) |
| Entire patient cohort (N = 732) (n %) | |
| Age (median), y | 62 (15-91) |
| <40 y, N | 82 (11.2) |
| ≥40 to < 60 y, N | 237 (32.4) |
| ≥60 y, N | 413 (56.4) |
| Gender | |
| Female, N | 295 (40.6) |
| Male, N | 437 (59.7) |
| Diagnosis | |
| AML, N | 206 (28.1) |
| ALL, N | 35 (4.8) |
| CML, N | 13 (1.8) |
| CLL, N | 31 (4.2) |
| Other MPN, N | 11 (1.4) |
| MDS, N | 63 (8.6) |
| Hodgkin lymphoma, N | 12 (1.6) |
| Non-Hodgkin lymphoma, N | 141 (19.3) |
| Multiple myeloma, N | 97 (13.3) |
| Solid tumor, N | 90 (12.3) |
| Other hematological disease, N | 50 (6.8) |
| Healthy individual, N | 11 (1.5) |
| Therapy | |
| Allogeneic SCT, N | 196 (26.8) |
| Autologous SCT, N | 58 (7.9) |
| Prior chemotherapy, N | 435 (59.4) |
| Prior radiation, N | 186 (25.4) |
| Unknown, N | 45 (6.1) |
| alloSCT patient cohort (N = 196) | |
| Disease status at the time of alloSCT | |
| CR | 81 (41.3) |
| PR | 33 (16.8) |
| SD, refractory or progressive disease | 71 (36.2) |
| Unknown | 11 (5.7) |
| Conditioning regimen | |
| MAC | 34 (17.3) |
| RIC | 142 (72.4) |
| NMA | 14 (7.1) |
| Unknown | 6 (3.1) |
| GvHD prophylaxis | |
| CsA + MMF | 130 (66.3) |
| CsA + MTx | 43 (21.9) |
| CNI + MMF + PTCy | 9 (4.6) |
| Other/unknown | 14 (7.2) |
| Use of ATG | 153 (78.1) |
Numbers refer to individuals in the entire cohort or the alloSCT cohort as indicated. If multiple samples were obtained from one individual, data from this individual are included only once.
ALL, acute lymphoblastic leukemia; ATG, anti-thymocyte globuline; CLL, chronic lymphatic leukemia, CML, chronic myeloid leukemia; CNI, calcineurin inhibitor (CsA or tacrolimus); CsA, cyclosporine A; CR, complete remission; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate; MPN, myeloproliferative neoplasia; MTx, methotrexate; NMA, nonmyeloablative conditioning; PR, partial remission; PTCy, post SCT cyclophosphamide; RIC, reduced intensity conditioning; SD, stable disease.